News from CRG
How can signs of disease be detected as early as possible at the cellular level so as to quickly prevent disease progression through appropriate treatment? The European Union is now investing a million euros over a one-year period in devising the plan for a fundamentally new approach to understanding the constant changes within cells and their relationships to one another, thus creating the foundation for the precision medicine of the future.
The funds will go to the international LifeTime consortium, which is jointly coordinated by the Max Delbrück Center for Molecular Medicine (MDC) and the Institut Curie. Two researchers at the Centro Nacional de Análisis Genómico (CNAG-CRG) of the Centre for Genomic Regulation (CRG) are involved in the project: Marc Marti-Renom, ICREA research professor, leader of the Structural Genomics group and co-chair of the Computational Biology workpackage of the LifeTime initiative and Holger Heyn, who has recently joined the consortium and leads the Single-Cell Genomics team at CNAG-CRG.
More than 120 scientists at 53 institutions in 18 European countries are supporting the LifeTime consortium, as are more than 60 partners from industry. The European Union will concurrently fund the preparation of five other potential research initiatives. After the first year of funding, it will be up to the European Union to decide if any of them will be continued as a large-scale research initiative.